46. Malignant rheumatoid arthritis Clinical trials / Disease details

Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-004131-84-NL (EUCTR)	14/02/2022	08/09/2021	Comparing the effectiveness of tofacitinib extended release (XR) chronotherapy, morning versus evening dosing, in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients from a patient’s, clinical as well as a translational point of view.	Chronotherapy in Inflammatory Arthritis (ChronIA trial): a crossover randomized controlled trial comparing the effectiveness of morning and evening dosing of tofacitinib extended-release - ChronIA trial	Rheumatoid arthritis or psoriatic arthritis according to respectively 2010 criteria or CASPAR criteria MedDRA version: 23.1;Level: PT;Classification code 10039073;Term: Rheumatoid arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 21.0;Level: LLT;Classification code 10037160;Term: Psoriatic arthritis;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Xeljanz XR Product Name: Tofacitinib XR Product Code: EMEA/H/C/004214	Erasmus Medical Center	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	84	Phase 4	Netherlands
2	NCT04876781 (ClinicalTrials.gov)	November 1, 2021	20/4/2021	Korean Post-marketing Surveillance for Xeljanz XR	Korean Post-marketing Surveillance for Xeljanz XR (Registered)	Active Moderate to Severe Rheumatoid Arthritis;Active Ankylosing Spondylitis	Drug: Tofacitinib XR	Pfizer	NULL	Not yet recruiting	18 Years	N/A	All	200		NULL